BD Q2 fiscal 2025: Revenue $5.27B (+4.5%), GAAP EPS $1.07 (down 42% YoY), adj. EPS $3.35

BECTON DICKINSON & CO

2025-Q2 EPS reported $2.11 vs consensus $3.44 ▼ miss (-38.6%)

Revenue increased 4.5% as reported to $5.272B; organic growth 0.9%, currency-neutral growth 6.0%.
GAAP diluted EPS $1.07, down 42.2% YoY; adjusted diluted EPS $3.35, up 5.7% YoY.
Company updates full-year fiscal 2025 guidance and provides estimated tariff impact; specific numbers not detailed.
Announces intention to invest $2.5B in U.S. manufacturing capacity over next 5 years.
Business highlights include FDA clearances for Phasix ST Umbilical Hernia Patch and advanced microbiology solution.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.